April 22, 2026
SEIKAGAKU CORPORATION
(Securities Code: TSE 4548)

Seikagaku Announces Marketing Approval in Japan for SI-449, an Adhesion Barrier, and Decision on Sales Partner

Seikagaku Corporation (Tokyo, Japan; "Seikagaku") announced today that on April 20, 2026 it obtained marketing approval for SI-449, a surgical adhesion barrier (product name: cs barrier®). Seikagaku also announced that it has decided on Covidien Japan Inc. (Tokyo, Japan; "Covidien Japan") as a sales partner in Japan for SI-449.

Covidien Japan, the sales partner for SI-449, is a Japanese subsidiary of Medtronic, a global manufacturer of medical devices. Covidien Japan is responsible for providing solutions in the fields of surgery and minimally invasive treatment and diagnosis and has an extensive portfolio with a strong presence in medical fields including gastroenterological surgery and gynecology, the primary application areas for SI-449. Accordingly, synergies between its portfolio and SI-449 are expected.

In its capacity as manufacturer, Seikagaku supports the activities of sales partners through means including the provision of academic information. By disseminating SI-449, Seikagaku will aim to contribute to healthy and fulfilling lives for patients and improve quality of life by reducing the risk of occurrence of complications associated with postoperative adhesions.

After the insurance reimbursement price has been obtained, Seikagaku will announce the launch timing following consultation with Covidien Japan.
Furthermore, the impact of this matter is expected to be incorporated into the Forecast of Consolidated Financial Results for Fiscal 2026, to be disclosed in the Consolidated Financial Results (Summary) for Fiscal 2025, scheduled for release on May 13, 2026.

Reference Information
<About SI-449>
SI-449 is a powdered adhesion barrier whose main ingredient is cross-linked chondroitin sulfate developed using Seikagaku's own glycosaminoglycan*1 cross-linking technology.
A pivotal trial conducted in Japan in the field of gastrointestinal surgery has confirmed that SI-449, which has the property of absorbing moisture and swelling, forms a barrier between the surgical wound and surrounding tissues after application, thereby demonstrating efficacy in preventing postoperative adhesions.
Furthermore, this material is composed of substances naturally found in the body, including cross-linking agents, and its safety has been confirmed in the clinical trials conducted in Japan.
Additionally, because it is a powdered formulation, it easily covers uneven tissue surfaces; the pilot trials conducted in Japan in the field of gynecology have confirmed that it offers excellent operability during laparoscopic surgery, a procedure that is becoming increasingly widespread.

*1 Glycosaminoglycans (GAGs) are a major component of glycoconjugates. Chondroitin sulfate and hyaluronic acid are GAGs.

#######